Paratek Appoints Dennis Molnar as CEO and Evan Loh as Chair – Private Equity Hub

Additional programs at Paratek include a narrow spectrum tetracycline-derived small molecule optimized for acne and rosacea with a Phase 2 trial planned to begin later this year and preclinical programs for non-infective applications of the …

This entry was posted in News. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *


*